Pulmonary disease, chronic obstructive Trials in Białystok, Poland
Conditions / Pulmonary disease, chronic obstructive / Białystok, Poland
Research into Pulmonary disease, chronic obstructive spans multiple therapeutic approaches and trial phases.
21 total trials for this combination
Showing top 10 of 21 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02164513 | A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |
| NCT02105948 | Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients | COMPLETED | PHASE3 |
| NCT01126437 | Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease | COMPLETED | PHASE3 |
| NCT03345407 | Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) | TERMINATED | PHASE2 |
| NCT02296138 | Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease. | COMPLETED | PHASE3 |
| NCT01313676 | Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease | COMPLETED | PHASE3 |
| NCT04133909 | Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level | COMPLETED | PHASE3 |
| NCT00268216 | Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |
| NCT00563381 | Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients. | COMPLETED | PHASE4 |
| NCT01053988 | A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE3 |